stoxline Quote Chart Rank Option Currency Glossary
  
Armata Pharmaceuticals, Inc. (ARMP)
3.01  -0.01 (-0.31%)    07-19 14:06
Open: 3.15
High: 3.1699
Volume: 3,256
  
Pre. Close: 3.02
Low: 3.01
Market Cap: 109(M)
Technical analysis
2024-07-19 1:48:43 PM
Short term     
Mid term     
Targets 6-month :  3.98 1-year :  4.65
Resists First :  3.41 Second :  3.98
Pivot price 2.85
Supports First :  2.8 Second :  2.42
MAs MA(5) :  3.07 MA(20) :  2.84
MA(100) :  3.05 MA(250) :  2.96
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  74.6 D(3) :  75.5
RSI RSI(14): 57.3
52-week High :  5.26 Low :  1.23
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ARMP ] has closed below upper band by 16.6%. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.27 - 3.29 3.29 - 3.31
Low: 2.98 - 3 3 - 3.02
Close: 2.99 - 3.02 3.02 - 3.05
Company Description

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Headline News

Fri, 12 Jul 2024
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Receives Buy Rating from HC Wainwright - Defense World

Thu, 11 Jul 2024
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat

Thu, 11 Jul 2024
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns Buy Rating from HC Wainwright - MarketBeat

Thu, 11 Jul 2024
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - StockTitan

Thu, 11 Jul 2024
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire

Thu, 11 Jul 2024
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 - Quantisnow

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 36 (M)
Shares Float 11 (M)
Held by Insiders 69.5 (%)
Held by Institutions 3.5 (%)
Shares Short 91 (K)
Shares Short P.Month 100 (K)
Stock Financials
EPS -1.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.35
Profit Margin 0 %
Operating Margin -843.8 %
Return on Assets (ttm) -25.4 %
Return on Equity (ttm) -358.7 %
Qtrly Rev. Growth -8.4 %
Gross Profit (p.s.) -0.82
Sales Per Share 0.11
EBITDA (p.s.) -1.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -50 (M)
Levered Free Cash Flow -31 (M)
Stock Valuations
PE Ratio -1.93
PEG Ratio 0
Price to Book value -9.33
Price to Sales 28.29
Price to Cash Flow -2.31
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android